Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00367718
Recruitment Status : Withdrawn (PI left JHU and is not able to be reached for updates)
First Posted : August 23, 2006
Last Update Posted : May 18, 2020
Sponsor:
Collaborator:
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
This study seeks to test the Efficacy in terms of rates of disease response in metastatic nasopharyngeal carcinoma of the standard dose of velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule. The study uses a Simons 2 stage design and will enroll between 15-25 patients. Secondary endpoints studied include Pharmacokinetics, toxicities, EBV viral load and molecular characterization of EBV in plasma.

Condition or disease Intervention/treatment Phase
Nasopharyngeal Carcinoma Drug: Velcade Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

Resource links provided by the National Library of Medicine

Drug Information available for: Bortezomib


Intervention Details:
  • Drug: Velcade
    velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.


Primary Outcome Measures :
  1. Efficacy based on response of measurable disease [ Time Frame: duration of study (4 -6 months) ]

Secondary Outcome Measures :
  1. EBV viral load [ Time Frame: duration of study (4 -6 months) ]
  2. toxicities [ Time Frame: duration of study (4 -6 months) ]
  3. molecular characterization of EBV in Plasma [ Time Frame: duration of study (4 -6 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy proven nasopharyngeal carcinoma - WHO type 3 (recurrence or metastases)
  • metastatic disease or locally recurrent disease not amendable curative therapy
  • Patients must have measurable disease
  • least one (not more than a total of three prior lines of chemotherapy for metastatic or recurrent disease). This must include at least 1 prior line of platinum-containing chemotherapy.
  • An ECOG performance status of 0-2
  • Absolute neutrophil count (ANC) ≥1500/mm3
  • Hemoglobin 8g/dl (blood transfusion is allowed to correct hemoglobin level).
  • PLT ≥ 75,000/mm 3
  • Total bilirubin ≤ 2 x upper normal limit (UNL)
  • Serum ALT ≤ 5 x UNL
  • Serum creatinine ≤ 2 mg/dL
  • Serum albumin ≥ 2.5 g/dL
  • No known history of brain or leptomeningeal metastasis.
  • ≥ 18 years of age.
  • Estimated life expectancy ≥ 24 weeks.
  • For sexually active women of childbearing potential, negative pregnancy test within 21 days of enrolling on trial.
  • must be able to give informed written consent

Exclusion Criteria:

  • Patients who have not had at least 1 or more than 3 previous lines of treatment for metastatic or recurrent NPC
  • Prior BORTEZOMIB therapy
  • Immunotherapy ≤ 4 weeks have elapsed prior to study entry
  • Biologic therapy ≤ 4 weeks have elapsed prior to study entry
  • Radiation therapy ≤ 4 weeks have elapsed prior to study entry
  • Major surgery, or significant traumatic injury ≤3 weeks prior to study entry
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or supportive care considered investigational
  • Evidence of CNS involvement
  • Presence of > grade 1 sensory peripheral neuropathy of any etiology OR grade 1 with neuropathic pain of any etiology.
  • Patients with significant local symptoms from metastases which is amenable to radiotherapy
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BORTEZOMIB.
  • History of other malignancy ≤ 3 years prior to study entry, except for adequately treated basal cell, squamous cell skin cancer or cervical intraepithelial neoplasia.
  • Uncontrolled intercurrent illness
  • Patients who are pregnant or breast feeding (Sexually active men and women of childbearing potential must use contraception during course of therapy and within 3 months of completion of trial) Participation in another clinical trial involving therapeutic intervention within 4 weeks of enrollment.
  • Known history of HIV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367718


Locations
Layout table for location information
China
Chinese University of Hong Kong
Hong Kong, China
Singapore
Johns Hopkin Singapore International Medical Center
Singapore, Singapore
National University Hospital of Singapore
Singapore, Singapore
Sponsors and Collaborators
Johns Hopkins University
Janssen-Cilag Ltd.
Investigators
Layout table for investigator information
Study Chair: Wen-son Hsieh, M.D. Johns Hopkins Singapore-International Medical Center
Study Chair: Brigette Ma, M.D. Chinese University of Hong Kong
Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00367718    
Other Study ID Numbers: CTRG-NP04/23/06
First Posted: August 23, 2006    Key Record Dates
Last Update Posted: May 18, 2020
Last Verified: May 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Nasopharyngeal Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Nasopharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Bortezomib
Antineoplastic Agents